The ACC’s Heart Failure and SGLT2is: The New Pillar in Care Initiative is designed to provide practical guidance for clinicians on the implementation of sodium-glucose cotransporter-2 inhibitors (SGLT2i) …

SGLT2 inhibitors were added to heart failure guidelines in 2022. Dapagliflozin and empagliflozin have shown benefits in patients with HFrEF, HFpEF, and HFmrEF with or without diabetes.7 SGLT2 …

Jun 3, 2025 · SGLT2 inhibitors have become an important class of medication in managing heart failure. Initially developed to treat diabetes, these drugs have shown clear benefits for patients with heart …

Apr 7, 2025 · Early introduction of sodium–glucose cotransporter 2 inhibitors in settings of acute heart failure improves all‐cause death and rehospitalization rates.

Mar 13, 2023 · Abstract Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are the latest addition to guideline-directed medical therapy in heart failure (HF) with reduced ejection fraction with recent …

ABSTRACT Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are the latest addition to guideline-di-rected medical therapy in heart failure (HF) with reduced ejection fraction with recent trials …

Apr 26, 2023 · Abstract The sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to reduce risks of clinical events in patients with heart failure (HF), with early and sustained benefits …

Abstract Background Heart failure (HF) is a clinical diagnosis of a condition that develops secondary to either left ventricular systolic or diastolic functions. Lately, inhibitors of sodium-glucose cotransporter …

Do sodium-glucose cotransporter-2 (SGLT-2) inhibitors improve cardiovascular outcomes in patients who have heart failure with preserved ejection fraction (HFpEF)?

Dec 9, 2025 · Sotagliflozin (Inpefa) (dual SGLT1/2 inhibitor for heart failure; not for blood‑sugar control) SGLT2 inhibitors help the kidneys excrete excess glucose into the urine, which lowers blood sugar.